<!DOCTYPE html>
<html lang="en"><!-- InstanceBegin template="/Templates/alhill.dwt" codeOutsideHTMLIsLocked="false" -->
  <head>
    <meta charset="UTF-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="author" content="Alison Hill">
	<meta name="copyright" content="Copyright (c) 2021 Alison Hill">
	<meta name="description" content="Alison Hill, Johns Hopkins University/Harvard University">
	<meta name="keywords" content="Alison Hill, Alison Lynn Hill, Alison L Hill, Alison Hill Harvard, Ali Hill, Harvard, Johns Hopkins, Biomedical Engineering, Program for Evolutionary Dynamics, Institute for Computational Medicine, Infectious Disease Dynamics Group, evolution, biophysics, mathematical modeling, mathematical biology, computational biology, viral dynamics, evolutionary dynamics, systems biology, HIV, AIDS, drug resistance">
	<meta http-equiv="imagetoolbar" content="false">
	<!-- InstanceBeginEditable name="doctitle" -->
	<title>Alison Hill, Johns Hopkins University</title>
	<!-- InstanceEndEditable -->
	<!-- Bootstrap -->
	<link href="css/bootstrap.css" rel="stylesheet">
    <link href="css/custom.css" rel="stylesheet">

	<!-- HTML5 shim and Respond.js for IE8 support of HTML5 elements and media queries -->
	<!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
	<!--[if lt IE 9]>
		  <script src="https://oss.maxcdn.com/html5shiv/3.7.2/html5shiv.min.js"></script>
		  <script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
		<![endif]-->
  <!-- InstanceBeginEditable name="head" -->
  <!-- InstanceEndEditable -->
    <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-53859205-1', 'auto');
  ga('send', 'pageview');

</script>
	 <script src="https://kit.fontawesome.com/8c1a250531.js" crossorigin="anonymous"> </script>
  </head>
  

  
<body>
	<!-- jQuery (necessary for Bootstrap's JavaScript plugins) --> 
	<script src="js/jquery-1.11.2.min.js"></script>

	<!-- Include all compiled plugins (below), or include individual files as needed --> 
	<script src="js/bootstrap.js"></script>
    
           <nav class="navbar navbar-default">
              <div class="container-fluid">
                <div class="navbar-header">
                  <a class="navbar-brand" href="#"></a>
                </div>
                <ul class="nav navbar-nav navbar-right">
                  <li><a href="index.html">About</a></li>
                  <li><a href="research.html">Research</a></li>
                  <li><a href="papers.html">Papers</a></li>
                  <li><a href="team.html">Team</a></li>
                  <li><a href="more.html">More</a></li>
                </ul>
              </div>
</nav>
    
    <div class="container-fluid">
    
        <div class="row">
          <div class="col-sm-2" align="right"><img src="images/virus_w_dynamics2.png" alt="virus" width="75" class="img-responsive"></div>
          <div class="col-sm-10"><h1>Hill Lab @JohnsHopkins</h1>  </div>
        </div>
  		
      <div class="row">
        	<div class="col-sm-12" align="right">
             <hr style="background-color:indigo; height: 2px">
            </div>    
        </div>
        
        <!--
        <div class="row" style="background-color:indigo; height:150px">
          <div class="col-sm-2" align="right"><img src="../images/virus_w_dynamics2_rev.png" alt="virus" width="75" class="img-responsive"></div>
          <div class="col-sm-10"><h1 style="color:white">Alison L Hill</h1>  </div>
        </div>
        
       <div class="row">
        	<div class="col-sm-12" align="right">
             <hr>
            </div>    
        </div>
  		-->
        
      <!-- InstanceBeginEditable name="EditBody" -->
<div class="row">
        <div class="col-md-1"></div>
        <div class="col-md-10">
        <h3> COVID-19 Vaccine Comparison Table </h3>
       
<br>

<table class="table table-compressed table-striped">
	<thead>
		<tr><th style="width: 8.5%"></th><th style="width: 8.5%"></th><th style="width: 18.5%">Moderna</th><th style="width: 18.5%">Pfizer-BioNTech</th><th style="width: 18.5%">Johnson &amp; Johnson</th><th style="width: 18.5%">AstraZeneca</th></tr>
	</thead>
	<tbody>
		<tr><td><strong>Basics</strong></td><td></td><td></td><td></td><td></td><td></td></tr>
		<tr><td>Research Name</td><td></td><td>mRNA-1273</td><td>BNT162b2</td><td>Ad26.COV2.S</td><td>AZD1222 <br>
ChAdOx1 nCoV-19</td></tr>
		<tr><td>INN</td><td></td><td></td><td>tozinameran</td><td></td><td></td></tr>
		<tr><td>Trade Name</td><td></td><td></td><td>Comirnaty</td><td></td><td>Covishield<br>
		  Vaxzevria</td></tr>
		<tr><td>Type</td><td></td><td>mRNA</td><td>mRNA</td><td>Viral vector (Ad26) + DNA</td><td>Viral vector (ChAdOx1) + DNA</td></tr>
		<tr><td>Antigen</td><td></td><td>Spike</td><td>Spike</td><td>Spike</td><td>Spike</td></tr>
		<tr><td>Administration</td><td></td><td>Intramuscular injection</td><td>Intramuscular injection</td><td>Intramuscular injection</td><td>Intramuscular injection</td></tr>
		<tr><td>Doses</td><td></td><td>2</td><td>2</td><td>1</td><td>2</td></tr>
		<tr><td>Dose interval</td><td></td><td>28 days</td><td>21 days </td><td>NA</td><td>4-12 weeks</td></tr>
		<tr><td>Approved in US?</td><td></td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td></tr>
        <tr><td>Age Approved For (US)</td><td></td><td>18+</td><td>16+</td><td>18+</td><td>NA</td></tr>
		<tr><td>Storage Temp</td><td></td><td>Freezer (Long term)<br>
		  Refrigerator (30 days)</td><td>Ultra-cold freezer (Long term) <br>
  Freezer (2 weeks) <br>
  Refrigerator (5 days)</td><td>Refrigerator (3 months)</td><td>Refrigerator</td></tr>
		<tr><td><strong>Efficacy</strong></td><td></td><td></td><td></td><td></td><td></td></tr>
		<tr><td rowspan="2">Deaths</td><td>All doses</td><td>100% [1] </td><td></td><td>100% [16]</td><td>100% [17]</td></tr>
		<tr><td>Dose 1 only</td><td></td><td>72% [12]</td><td>NA</td><td></td></tr>
		<tr><td rowspan="2">Severe Disease</td><td>All doses</td><td>100% [1] <br>
		  95% [13]</td><td>75% [5] <br>
		    95% [11] <br>
		    92% [12]</td><td>85% [16] <br>
		      86% (US) [16] <br>
		      82% (ZA) [16] <br>
		      88% (BR) [16]</td><td>100% [17] <br>
          100% [18]</td></tr>
		<tr><td>Dose 1 only</td><td></td><td>62% [12] <br>
		  85% [22]</td><td>NA</td><td>94% [22]</td></tr>
		<tr><td rowspan="2">Symptomatic Infection</td><td>All doses</td><td>94% [1] <br>
		  90% [13]</td><td>95% [5] <br>
		    97% [9] <br>
		    91% [11] <br>
		    94% [12]</td><td>66% [16] <br>
		      72% (US) [16] <br>
		      64% (ZA) [16] <br>
		      68% (BR) [16]</td><td>55% (&lt;6 wks btwn doses) [17] <br>
		        81% (&gt;12 wks btwn doses) [17] <br>
          76% (4 weeks betwen doses) [18]</td></tr>
		<tr><td>Dose 1 only</td><td></td><td>87% [6] <br>
		  85% [10] <br>
		  57% [12]</td><td>NA</td><td>76% (3-12 wks after dose) [17]</td></tr>
		<tr><td rowspan="2">Any Infection</td><td>All doses</td><td>90% [2]</td><td>90% [2] <br>
		  85% [4] <br>
		  92% [12]</td><td></td><td>47% (&lt;6 wks btwn doses) [17] <br>
	      60% (&gt;12 wks btwn doses) [17]</td></tr>
		<tr><td>Dose 1 only</td><td>80% [2]</td><td>80% [2] <br>
70% [4] <br>
75% [10] <br>
46% [12]<br>
70% [30]<br></td><td>NA</td><td>64% (3-12 weeks after dose) [17]<br>
  60% (3-6 weeks after dose) [30]<br></td></tr>
		<tr><td rowspan="2">Asymptomatic Infection</td><td>All doses</td><td></td><td>94% [9]</td><td>60% [16]</td><td>0% (&lt;6 wks btwn doses) [17] <br>
		  20% (&gt;12 wks btwn doses) [17]</td></tr>
		<tr><td>Dose 1 only</td><td>62% [1]</td><td>75% [7]</td><td>NA</td><td>0% (3-12 weeks after dose) [17]</td></tr>
		<tr><td colspan="2"><strong>Special Populations</strong></td><td></td><td></td><td></td><td></td><td></td></tr>
		<tr><td>Pregnant/Lactating Women</td><td></td><td>Data limited, not contraindicated</td><td>Data limited, not contraindicated. Trial underway NCT04754594</td><td>Data limited, not contraindicated. Trials underway</td><td>No data reported on pregnant women from clinical trials. UK recommendations are for pregnant women to get Moderna or Pfizer vaccine.</td></tr>
		<tr><td>Children</td><td></td><td>Trials underway (KidCOVE, TeenCOVE)</td><td>Preliminary results: efficacy of 100% in children ages 12-15 [8]. Trials underway for children 0-11</td><td>Trials underway</td><td>Trials underway in children ages 6-17</td></tr>
		<tr><td>Previously infected</td><td></td><td>Vaccination recommended <br>
		    <br>
		    Studies show when those with previous infection are given a single dose of vaccine, existing antibody levels rise and become equal or greater to those seen after the second dose of vaccine in individuals without a prior history of infection [15]</td><td>Vaccination recommended<br>
		      <br>
		      Studies show when those with previous infection are given a single dose of vaccine, existing antibody levels rise and become equal or greater to those seen after the second dose of vaccine in individuals without a prior history of infection [14,15]</td><td>Vaccination recommended<br>
		        <br>
		        Too few events among previously infected individuals included in trials (e.g. [16]) to inform efficacy measures</td><td>Vaccination recommended<br>
		          <br>
          Too few events among previously infected individuals included in trials (e.g. [17][18]) to inform efficacy measures</td></tr>
		<tr><td colspan="2"><strong>Efficacy against variants</strong></td><td></td><td></td><td></td><td></td><td></td></tr>
		<tr><td>B.1.1.7 ("UK variant")</td><td></td><td>Laboratory titres of neutralizing Ab against this variant in vaccinated individuals were not changed [24]</td><td>During study [4], B1.1.7 was dominant variant in UK, suggesting high efficacy. Similar situation in study [9] in Israel. Another study in Israel [25] found that B.1.1.7 was overrepresented among breakthrough infections that occured in partially vaccinated individuals compared to unvaccinated individuals, suggesting some partial escape of immunity before it is maximized by the booster dose. Laboratory studies of titres of neutralizing Ab against this variant in vaccinated individuals were only slightly lower (2-3 times) [23]. </td><td></td><td>Study [20] in the UK found that no significant difference in vaccine efficacy at preventing symptomatic disease with B.1.1.7 compared to other strains. However they did find that the levels of neutralizing Ab from vaccinated individuals against B.1.1.7 were lower. </td></tr>
		<tr><td>B.1.351 ("South African variant")</td><td></td><td>Laboratory titres of neutralizing Ab against this variant in vaccinated individuals were moderately lower (~6 fold) [24]. Company has developed a variant -specific booster shot, which appears to produce neutralizing Ab against this strain in mice, and is currently undergoing Phase 2 studies [13]</td><td>Study [11] included an analysis of efficacy in ZA, where B.1.135 is prevalent, and found 100% efficacy. 6/9 sequenced infections in placebo group were caused by B.1.135 variant. A study in Israel [25] found that B.1.135 was overrepresented among breakthrough infections that occured in fully vaccinated individuals compared to unvaccinated individuals, suggesting some partial escape of immunity. </td><td>The majority of sequenced infections in ZA in [16] were caused by B.1.1.135, suggesting an explanation for the slightly lower vaccine efficacy compared to in the US</td><td>Study [17] was performed before B.1.1.35 was widespread in ZA. In follow-up, efficacy against symptomatic disease after 2 doses 3-5 weeks apart was reduced to 10% against B.1.1.135 in ZA [19]. Laboratory titres of neutralizing Ab against this variant in vaccinated individuals were also lower. Booster shots including mutated Spike sequence are under development</td></tr>
		<tr><td>P.1. ("Brazil variant")</td><td></td><td></td><td>Laboratory titres of neutralizing Ab against this variant in vaccinated individuals were only slightly (2-3 times) lower [21]. </td><td>All of the sequenced infections from BR in [16] were caused by non-P1 strains, suggesting the trial does not inform on vaccine efficacy against P1</td><td>Study [17] was performed before P.1 was widespread in BR. Laboratory titres of neutralizing Ab against this variant in vaccinated individuals were only slightly (2-3 times) lower [21]. Booster shots including mutated Spike sequence are under development</td></tr>
		<tr><td colspan="2"><strong>Duration of protection</strong></td><td></td><td></td><td></td><td></td><td></td></tr>
		<tr><td>Measured by antibody titers/neutralization</td><td></td><td>100% of participants (N=33) had detectable neutralizating Ab at 6 months post vaccination, nAb half-life of ~2-6 months [3]</td><td></td><td></td><td></td></tr>
		<tr><td>Measured by efficacy against infection</td><td></td><td></td><td>Study [11] followed up individuals in original RCT for 6 months, found 91% efficacy</td><td></td><td></td></tr>
        <tr>
          <td><strong>Side effects</strong></td><td></td><td></td><td></td><td></td><td></td></tr>
		<tr><td>Local - Any &nbsp;(e.g. pain, swelling, or tenderness at injection site or lymph nodes)</td><td>Dose 1</td><td>84% [26]<br>
74% [28]</td><td>70% [27]<br>
  65% [28]<br>
  72% [30]</td><td>50% [29]</td><td>59% [30]<br>
    70% [31]</td></tr>
		<tr><td></td><td>Dose 2</td><td>89% [26]<br>
		  82% [28]</td><td>73% [27]<br>
  69% [28]<br>
  69% [30]</td><td>NA</td><td>46% [31]</td></tr>
		<tr><td>Local - Grade 3
(Prevented daily activity)</td><td>Dose 1</td><td>3% [26]</td><td></td><td>0.7% [29]</td><td>1.3% [31]</td></tr>
		<tr><td></td><td>Dose 2</td><td>7% [26]</td><td></td><td>NA</td><td>1% [31]</td></tr>
		<tr><td>Systemic - Any (e.g. fever/chills, fatigue, headache, muscle aches, nausea)</td><td>Dose 1</td><td>55% [26]<br>
  52% [28]</td><td>59% [27]<br>
  48% [28]<br>
  14% [30]</td><td>55% [29]</td><td>34% [30]<br>
  70% [31]</td></tr>
		<tr><td></td><td>Dose 2</td><td>79% [26]<br>
		  75% [28]</td><td>70% [27]<br>
		    64% [28]<br>
		    22% [30]</td><td>NA</td><td>45% [31]</td></tr>
		<tr><td>Systemic - Grade 3
(Prevented daily activity)</td><td>Dose 1</td><td>3% [26]</td><td></td><td>2% [29]</td><td>7% [31]</td></tr>
	<tr><td></td><td>Dose 2</td><td>16% [26]</td><td></td><td>NA</td><td>2% [31]</td></tr>
    </tbody>
</table>
<br>
<h4>
<a href="https://docs.google.com/spreadsheets/d/1Mr_pe1PXv8_NxJRxfikA31TvxflsVXypifiutSLsOVw/edit?usp=sharing"> Spreadsheet version </a> </h4>
<br>
<h4> Caveats </h4>
 
 <ul>
   <li> All efficacy values are approximations. They are limited by sample sizes and incidence of infections during studies. In most clinical trials, total #s of severe infections and deaths were very small, limiting calculations of efficacy for these outcomes. Efficacy values do not include confidence intervals (see original sources for those) </li>
   <li>For efficacy values after a single dose, there are some inconsistencies in the time after the dose the measurements start (e.g. 2 or 3 weeks) and how long they continue for (since timing of Dose 2 varies by region) </li>
   <li> When multiple efficacy values are given for a single outcome for the same vaccine, it is due to studies conducted in different countries (with different variants circulating) or different study designs (i.e randomized clinical trial versus cohort or case control study during mass vaccine rollout) </li>
   <li> For the Astra-Zeneca vaccine, efficacy values are only reported for patients who received the standard dose, not the subset of patients who received a low dose for their first dose and a standard dose for their second (since this is not what is being administered) </li>
   <li> The vaccine efficacy against asymptomatic infection can be less than 0%, if infections that would have been symptomatic are converted into being asymptomatic by vaccination, and if infections that would have been asymptomatic are not changed by vaccination. All values &lt;0% are reported as 0% here</li>
   <li>For data on side effects, individuals of all ages were grouped together. Note that these values are overestimates of the prevalence of side effects which are CAUSED by the vaccine, since they do not remove the (significant) fraction of placebo recipients who also reported side effects </li>
 </ul>
<br>
 

        
        <h4> References </h4>
        <p> *Before the link to each study is a brief description of the study size (e.g. N=30K means roughly 30,000 subjects), type of study (RCT = randomized controlled trial, CC = case control, or cohort), and the location. </p>
        <ol>
          <li>N=30K, RCT, USA <a href="https://www.nejm.org/doi/full/10.1056/nejmoa2035389">https://www.nejm.org/doi/full/10.1056/nejmoa2035389</a> Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 384, 403–416 (2021). </li>
          <li>N=4K, Cohort, USA <a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm">https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm</a> Thompson, M. G. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 70, (2021). </li>
          <li>N=33, Cohort, USA <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2103916">https://www.nejm.org/doi/full/10.1056/NEJMc2103916</a> Doria-Rose, N. et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine 0, null (2021)</li>
          <li>N=23K, Cohort, UK <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399</a> Hall, V. J. et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) (2021) doi:10.2139/ssrn.3790399. </li>
          <li>N=43K, RCT, Global <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2034577">https://www.nejm.org/doi/full/10.1056/NEJMoa2034577</a> Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 383, 2603–2615 (2020). </li>
          <li>N=43K, RCT, Global <a href="https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf">https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf</a> European Medicines Agency. Comirnaty: Public Assessment Report. 140 https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf (2021). </li>
          <li>N=9K, Cohort, UK <a href="https://doi.org/10.7554/eLife.68808">https://doi.org/10.7554/eLife.68808</a> Jones, N. K. et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife 10, e68808 (2021). </li>
          <li>N=2K, RCT, US <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal</a> Pfizer &amp; BioNTech. Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents (2021). </li>
          <li>N=6.4M, CC, Israel <a href="https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer">https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer</a> Pfizer &amp; BioNTech. Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared. https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer (2021). </li>
          <li>N=9K, Cohort, Israel <a href="https://doi.org/10.7554/eLife.68808">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/abstract</a> Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. &amp; Leshem, E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet 397, 875–877 (2021). </li>
          <li>N=43K, RCT, Global <a href="https://doi.org/10.7554/eLife.68808">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious</a> Pfizer &amp; BioNTech. Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study (2021). </li>
          <li>N=600K, CC, Israel <a href="https://doi.org/10.7554/eLife.68808">https://www.nejm.org/doi/10.1056/NEJMoa2101765</a> Dagan, N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine (2021) doi:10.1056/NEJMoa2101765. </li>
          <li>N=30K, RCT, USA <a href="https://www.businesswire.com/news/home/20210413006131/en/Moderna-Provides-Clinical-and-Supply-Updates-on-COVID-19-Vaccine-Program-Ahead-of-2nd-Annual-Vaccines-Day">https://www.businesswire.com/news/home/20210413006131/en/Moderna-Provides-Clinical-and-Supply-Updates-on-COVID-19-Vaccine-Program-Ahead-of-2nd-Annual-Vaccines-Day</a> Moderna. Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day. (2021). </li>
          <li>N=100, Cohort, Italy <a href="https://www.businesswire.com/news/home/20210413006131/en/Moderna-Provides-Clinical-and-Supply-Updates-on-COVID-19-Vaccine-Program-Ahead-of-2nd-Annual-Vaccines-Day">https://www.nejm.org/doi/full/10.1056/NEJMc2103825</a> Anichini, G. et al. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection. New England Journal of Medicine (2021). </li>
          <li>N=110, Cohort, USA <a href="https://www.businesswire.com/news/home/20210413006131/en/Moderna-Provides-Clinical-and-Supply-Updates-on-COVID-19-Vaccine-Program-Ahead-of-2nd-Annual-Vaccines-Day">https://www.nejm.org/doi/full/10.1056/NEJMc2101667</a> Krammer, F. et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. New England Journal of Medicine 384, 1372–1374 (2021). </li>
          <li>N=43K, RCT, Global. <a href="https://www.nejm.org/doi/10.1056/NEJMoa2101544">https://www.nejm.org/doi/10.1056/NEJMoa2101544</a> Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine. doi:10.1056/NEJMoa2101544. (2021). </li>
          <li>N=17K, RCT, Global <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14a822ff-f353-49f9-a7f2-21424b201e3b">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3</a> Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 397, 881–891 (2021). </li>
          <li>N=32K, RCT, US <a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html">https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html</a> AstraZeneca. AZD1222 US Phase III primary analysis confirms safety and efficacy</li>
          <li>N=2K, RCT, ZA <a href="https://www.nejm.org/doi/10.1056/NEJMoa2102214">https://www.nejm.org/doi/10.1056/NEJMoa2102214</a> Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine (2021) doi:10.1056/NEJMoa2102214. </li>
          <li>N=8K, RCT, UK <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0</a> Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet 397, 1351–1362 (2021). </li>
          <li>N=25, Cohort, UK <a href="https://www.biorxiv.org/content/10.1101/2021.03.12.435194v2.full">https://www.biorxiv.org/content/10.1101/2021.03.12.435194v2.full</a> Dejnirattisai, W. et al. Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2. bioRxiv 2021.03.12.435194 (2021) doi:10.1101/2021.03.12.435194. </li>
          <li>N=5.4M, Cohort, UK <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789264">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789264</a> Vasileiou, E. et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. (2021) doi:10.2139/ssrn.3789264. </li>
          <li>N=37, RCT, UK <a href="https://www.nature.com/articles/s41586-021-03412-7">https://www.nature.com/articles/s41586-021-03412-7</a> Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 1–10 (2021) doi:10.1038/s41586-021-03412-7 </li>
          <li>N=8, RCT, US <a href="https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1">https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1</a> Wu, K. et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv 2021.01.25.427948 (2021) doi:10.1101/2021.01.25.427948. </li>
          <li>N=800, CC, Israel <a href="https://www.medrxiv.org/content/10.1101/2021.04.06.21254882v2.full-text">https://www.medrxiv.org/content/10.1101/2021.04.06.21254882v2.full-text</a> Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. medRxiv 2021.04.06.21254882 (2021) doi:10.1101/2021.04.06.21254882.</li>
          <li>N=30K, RCT, US <a href="https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html">https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html</a> CDC. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine (2021). </li>
          <li>N=8K, RCT, US <a href="https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html">https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html</a> CDC. Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine (2021). </li>
          <li>N=3.6M, Cohort, US <a href="https://jamanetwork.com/journals/jama/fullarticle/2778441">https://jamanetwork.com/journals/jama/fullarticle/2778441</a> Chapin-Bardales, J., Gee, J. &amp; Myers, T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA (2021) doi:10.1001/jama.2021.5374. </li>
          <li>N=7K, RCT, US <a href="https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/reactogenicity.html">https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/reactogenicity.html</a> CDC. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine (J&amp;J) (2021). </li>
          <li>N=630K, Cohort, UK <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext</a> Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases (2021). </li>
          <li>N=5K, RCT, Global <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf</a> Medicines &amp; Heathcare products Regulatory Agency. COVID-19 Vaccine AstraZeneca, solution for injection in multidose container (ChAdOx1-S [recombinant]): Public Assessment Report. 58 (2021). </li>
        </ol>
<br>
<h4> Other Vaccine Resources </h4>
<ul>
  <li><a href="https://en.wikipedia.org/wiki/COVID-19_vaccine">https://en.wikipedia.org/wiki/COVID-19_vaccine</a></li>
  <li><a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html </a></li>
  <li><a href="https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines/">https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines/ </a></li>
  <li><a href="https://www.yalemedicine.org/news/covid-19-vaccine-comparison">https://www.yalemedicine.org/news/covid-19-vaccine-comparison </a></li>
  <li><a href="https://covid19.trackvaccines.org/">https://covid19.trackvaccines.org/</a></li>
  <li><a href="https://www.fda.gov/consumers/consumer-updates/learn-more-about-covid-19-vaccines-fda">https://www.fda.gov/consumers/consumer-updates/learn-more-about-covid-19-vaccines-fda</a>&nbsp;</li>
  <li><a href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html">https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html </a></li>
  <li><a href="https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/">https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/ </a></li>
  <li><a href="https://www.usatoday.com/in-depth/graphics/2021/03/27/comparing-covid-19-vaccines/6806600002/">https://www.usatoday.com/in-depth/graphics/2021/03/27/comparing-covid-19-vaccines/6806600002/</a></li>
  <li><a href="https://www.businessinsider.com/covid-vaccines-compared-vaccine-pfizer-oxford-moderna-astrazeneca-side-effects-2021-">https://www.businessinsider.com/covid-vaccines-compared-vaccine-pfizer-oxford-moderna-astrazeneca-side-effects-2021-</a>2 </li>
</ul>
<br>
<h4> <a href="covid19.html">Other Lab COVID-19 Resources</a>  </h4>
<br>

    </div>
        <div class="col-md-1"></div>
      </div>
<!-- InstanceEndEditable --></div>
    
        <footer class="footer">
			<div class="container-fluid">            
        		<div class="row">
                        <div class="col-sm-6" align="left"><img src="images/jhu.png"  alt="Johns Hopkins Logo" width="50"></div>
                        <div class="col-sm-6" align="right"><img src="images/harvard2.png"  alt="Harvard Logo" width="60"></div>
				</div>
          </div>
	
    	</footer>
  </body>
<!-- InstanceEnd --></html>
